Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow - PubMed (original) (raw)

Affiliations

PMID: 1712644

Free article

Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow

L K Ashman et al. Blood. 1991.

Free article

Abstract

The c-kit proto-oncogene product is a member of the family of growth factor receptors with intrinsic tyrosine kinase activity. In the mouse c-kit maps to the W locus, which is known to be of central importance in hematopoiesis. Monoclonal antibody (MoAb) YB5.B8, which was raised against peripheral blood blast cells from a patient with acute myeloid leukemia (AML), was recently shown to bind to the extracellular domain of the c-kit product. This antibody does not bind detectably to normal peripheral blood cells and identifies a sub-group of AML patients with poor prognosis. We have used MoAb YB5.B8 to study the expression of c-kit by normal human bone marrow cells by immunofluorescence and flow cytometry, and to isolate multipotential and erythroid colony-forming cells. In a series of 11 normal adult bone marrow specimens, MoAb YB5.B8 bound to 4.0% +/- 1.8% of the cells in the low-density fraction. Dual-labeling experiments were performed with YB5.B8, and CD33, CD34, and CD10 MoAbs. Three populations of cells binding YB5.B8 could be identified based on their pattern of coexpression of the other markers; ie, YB5.B8+/CD34+/CD33-, YB5.B8+/CD34+/CD33+ and YB5.B8+/CD34+/CD33+. These populations had distinctive two-dimensional light scatter characteristics and are likely to correspond to precursor colony-forming cells, colony-forming cells, and maturing mast cells, respectively. No cells binding both YB5.B8 and an MoAb to the early lymphoid marker CD10 were found, implying that most early lymphoid cells do not express c-kit. MoAbs to the c-kit protein should prove valuable in multimarker studies of human hematopoietic stem and progenitor cells. Definition of a reference range of c-kit expression in normal human bone marrow will provide a sound basis for further studies of this marker in diagnosis and prognosis in AML.

PubMed Disclaimer

Cited by

Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells.
Abbaspour Babaei M, Kamalidehghan B, Saleem M, Huri HZ, Ahmadipour F. Abbaspour Babaei M, et al. Drug Des Devel Ther. 2016 Aug 1;10:2443-59. doi: 10.2147/DDDT.S89114. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27536065 Free PMC article. Review.
Antagonism of stem cell factor/c-kit signaling attenuates neonatal chronic hypoxia-induced pulmonary vascular remodeling.
Young KC, Torres E, Hehre D, Wu S, Suguihara C, Hare JM. Young KC, et al. Pediatr Res. 2016 Apr;79(4):637-46. doi: 10.1038/pr.2015.275. Epub 2015 Dec 24. Pediatr Res. 2016. PMID: 26705118 Free PMC article.
Role of CD135/CD117 on Prognosis and Overall Survival of Acute Myeloid Leukemia.
Raeisi M, Nikhanfar AR, Nejate B, Movassaghpour Akbari AA, Dolatkhah R, Roosta Y, Sanaat Z. Raeisi M, et al. Asian Pac J Cancer Prev. 2019 Sep 1;20(9):2625-2631. doi: 10.31557/APJCP.2019.20.9.2625. Asian Pac J Cancer Prev. 2019. PMID: 31554356 Free PMC article.
Dendritic cell c-kit signaling and adaptive immunity: implications for the upper airways.
Oriss TB, Krishnamoorthy N, Ray P, Ray A. Oriss TB, et al. Curr Opin Allergy Clin Immunol. 2014 Feb;14(1):7-12. doi: 10.1097/ACI.0000000000000019. Curr Opin Allergy Clin Immunol. 2014. PMID: 24300419 Free PMC article. Review.
Stem cell growth factor receptor in canine vs. feline osteosarcomas.
Wolfesberger B, Fuchs-Baumgartinger A, Hlavaty J, Meyer FR, Hofer M, Steinborn R, Gebhard C, Walter I. Wolfesberger B, et al. Oncol Lett. 2016 Oct;12(4):2485-2492. doi: 10.3892/ol.2016.5006. Epub 2016 Aug 12. Oncol Lett. 2016. PMID: 27698817 Free PMC article.

Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow - PubMed (original) (raw)